Sermorelin

Intravenous
Diagnosis of growth hormone deficiency

Subcutaneous
Growth hormone deficiency

Not to be used in children whose growth hormone response to stimulation tests is inadequate. DM or epilepsy. Evaluate thyroid status before and during therapy. Uncontrolled hypothyroidism, obesity, elevated plasma fatty acids. Treatment should be stopped once epiphyses have closed. Pregnancy, lactation.

Tightness in the chest, facial flushing, urticaria, pain at the inj site, headache, nausea, vomiting, dysgeusia.

Preparations that contain or release somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors may interfere with the diagnostic efficacy. Serum levels of growth hormone may be increased when used with clonidine and levodopa. Efficacy may be reduced when used with antimuscarinic or antithyroid drugs.

May increase serum levels of inorganic phosphorus and alkaline phosphatase.

Description: Sermorelin is a synthetic 29-amino acid peptide that corresponds to the amino-terminal segment of the growth hormone releasing hormone. It stimulates the pituitary gland to increase the release of growth hormone.
Pharmacokinetics:
Absorption: Average bioavailability after SC admin is about 6%.
Excretion: Rapidly cleared from circulation. Half-life is about 11-12 min after IV or SC admin.

Store at 2-8°C.

Trophic Hormones & Related Synthetic Drugs